[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621033":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":44,"responsibleParty":56,"collaborators":42,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":60,"sex":66,"minAge":67,"maxAge":42,"enrollmentInfo":68,"targetDuration":42,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":77,"overallStatus":79,"whyStopped":42,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Chong Kun Dang Pharmaceutical","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Expermental group 1","EXPERIMENTAL","Empamax® 10mg",[13],"Drug: empagliflozin 10mg",{"label":15,"type":16,"description":17,"interventionNames":18},"Expermental group 2","ACTIVE_COMPARATOR","Amaryl® 1mg",[19],"Drug: Glimepiride 1mg",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","empagliflozin 10mg","once a day for 24 weeks",[9],[27],"Empamax 10mg",{"type":22,"name":29,"description":24,"armGroupLabels":30,"otherNames":31},"Glimepiride 1mg",[15],[32],"Amaryl 1mg",[34],{"name":35,"affiliation":36,"role":37},"In-Kyung Jeong, MD, PhD","Kyung Hee University Hospital at Gangdong","PRINCIPAL_INVESTIGATOR",[39],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},"CONTACT","+82-2-440-6126",null,"jik1016@naver.com",[45],{"facility":36,"status":42,"city":46,"state":42,"zip":42,"country":47,"countryCode":42,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Seoul","South Korea",{"type":49,"coordinates":50},"Point",[51,52],126.9784,37.566,{"lat":52,"lon":51},[55],{"name":35,"role":40,"phone":41,"phoneExt":42,"email":43},{"type":57,"investigatorFullName":42,"investigatorTitle":42,"investigatorAffiliation":42,"oldNameTitle":42,"oldOrganization":42},"SPONSOR","100621033","phase-4-evaluate-the-efficacy-and-safety-of-empagliflozin-or-glimepiride-combination-therapy-in-type-2-diabetes-mellitus-patients-100621033",false,"NCT07365358","Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients","A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients Inadequately Controlled With Metformin and Sitagliptin","EMPAGO","Inclusion Criteria:\n\n* Over 19 years old\n* Type 2 diabetes mellitus\n* Patient who has been taking oral hypoglycemic agents for over 8 weeks\n* Agreement with written informed consent\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or secondary diabetes mellitus\n* Patients with complications of severe diabetes such as proliferative diabetic retinopathy\n* Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption\n* Patients with abnormal laboratory test results according to the protocol\n* Continuous or non-continuous treatment with insulin for over 7 days within 12 weeks prior to screening\n* History of treatment with corticosteroids within 4 weeks prior to screening","ALL","19 Years",{"count":69,"type":70},200,"ESTIMATED","INTERVENTIONAL",[73],"PHASE4","The purpose of this study is to evaluate the efficacy and safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients",[76],"Diabete Type 2",[76,78],"Empagliflozin","NOT_YET_RECRUITING","2026-01-22",{"date":82,"type":83},"2026-01-26","ACTUAL",{"date":85,"type":70},"2026-03",{"date":87,"type":70},"2027-08",{"name":5,"class":6},1]